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The emergence and spread of multidrug-resistant tuberculosis (MDR-TB) poses a major
threat to the global targets for TB control. In recent years, an evolving science and
evidence base for MDR-TB has led to much needed changes in international guidelines
promoting the use of newer TB drugs and regimens for MDR-TB, however, there
remains a significant implementation gap. Due to the complexity of treating MDR-TB,
management of cases is often supported by an expert multidisciplinary team, or
clinical expert group. This service is often centralized, and may be delivered through
a telemedicine platform. We have implemented a Web-based “store-and-forward”
telemedicine service to optimize MDR-TB patient care in Daru, a remote and resource
limited setting in Papua New Guinea (PNG). From April 2016 to February 2019, 237
caseswere discussed using the service. This encompassed diagnostic (presumptive) and
treatment cases, and more recently, support to the scale up of preventative therapy for
latent TB infection. There were 75 cases in which the use of Bedaquiline was discussed
or mentioned, with a high frequency of discussions occurring in the initial period (26 cases
in the first 12 months), which has appeared to decrease as clinicians gained familiarity
with use of the drug (15 cases in the last 12 months). This service has supported high
quality clinical care and fostered collaboration between clinicians and technical experts
in a shared learning environment.
Keywords: tuberculosis, telemedicine, multidrug-resistant, resource-limited, clinical expert group, consilium,
digital health
INTRODUCTION
Tuberculosis (TB) is one of the top 10 causes of death globally and is the leading cause of death
from a single infectious agent. It is a disease that disproportionally affects low- and middle- income
countries, where it remains a major public health issue (1). The ambitious goal of theWorld Health
organization’s (WHO) End TB Strategy (2015–2035) is to eliminate TB as a public health threat,
targeting an incidence rate below 10 cases per 100,000 population per year. The three pillars of
the strategy are: integrated patient-centered TB care and prevention, bold policies and supportive
systems, and intensified research and innovation (2).
The emergence and spread of multidrug-resistant tuberculosis (MDR-TB, defined as
resistance to the most effective first-line anti-TB medications: rifampicin and isoniazid)
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poses a risk to achieving the End TB goals. MDR-TB is a
major contributor to mortality and the financial burden of the
antimicrobial-resistance threat (3). MDR-TB care is complex and
challenging and the burden is highest in settings where health
systems have significant challenges. Globally, patient outcomes
remain poor, with 55% of those enrolled completing treatment
successfully in 2016 (1), although success rates can be much
higher in well-resourced settings (4), and optimized programs
(1). The treatment duration for MDR-TB is lengthy (9 months to
2 years), with a regimen of potentially toxic medications, making
it more complex and more costly to deliver than drug-susceptible
TB (1). The WHO recommends a community-based model of
care for MDR-TB, which facilitates decentralization and scale-up
in high-burden and low resource settings.
In recent years, an evolving science and evidence base for
MDR-TB has led to much needed changes in international
guidelines promoting the use of newer TB drugs and regimens
for MDR-TB, with further changes anticipated in coming years
(5). However, there remains a major implementation gap,
with significant barriers to the knowledge-delivery (“know-do”)
pathway in MDR-TB care for a number of reasons (6). First,
knowledge and experience with managing complicated cases and
using the newer drugs such as bedaquiline and delamanid is
often limited to a few sites. These sites are typically centralized
specialist referral hospitals where expertise, training, clinical
advice and active drug safety monitoring can be provided.
Second, health workers may have limited training or capacity
in settings where MDR-TB care is needed most and is often
provided at decentralized sites.
Technical assistance and expertise, including clinical support,
either within a country or from international partners plays an
FIGURE 1 | “Digital health in tuberculosis program delivery.” In many countries, TB programs are structured across a number of levels: from the most peripheral (pink)
where patients may be located in village or community settings, to subnational levels (blue) where clinicians may be based at provincial or district health centers or
hospitals, to the national or supranational level (yellow) where technical advisors and national TB programs are based. There are a number of digital health applications
that have the potential to help bridge some of these “gaps”.
important role in optimizing MDR-TB in high burden/resource
limited settings (7). Telemedicine is one such modality of
providing clinical and technical assistance and can potentially
have a role in closing the “know-do” gap to improve patient
outcomes and quality of care.
We describe the global utility and experience with
telemedicine for MDR-TB care and our own experience with
the implementation of a Web-based telemedicine platform to
support MDR-TB care in a remote setting of Papua New Guinea
(PNG). This model has facilitated the delivery of technical
assistance to clinicians in the field through a store-and-forward
text-based platform suitable for the local context.
CURRENT ROLE AND GLOBAL
EXPERIENCE WITH TELEMEDICINE IN
MDR-TB CARE
Telemedicine is a broad term within the domain of digital
health, that encompasses a wide scope of practices, all relating
to the delivery of health care at a distance (8). Digital health
interventions and innovations have the potential to build upon
all three pillars of the End TB Strategy. The WHO has
released a digital health strategic agenda (9) describing different
approaches. The potential applications of digital health are broad
and may include: utilizing innovative approaches such as video-
observed therapy to allow for a more patient-centered approach,
applications for adherence support, remote patient consultations
and remote technical assistance including consensus expert
opinions for complex cases (referred to as TB “consilium” in
some settings) (see Figure 1).
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Due to the complexity of treating MDR-TB, which involves
long, complex and expensive regimens and close monitoring
for side effects, management of these cases is often supported
by an expert multidisciplinary team who provide advice and
guidance to the treating clinician. This group has been termed
a “TB consilium” in some settings (10), with origins in Eastern
European and former Soviet Union TB control programs. TB
consilia are typically centralized, with the ability to discuss the
most difficult cases at a higher level (e.g., national or supra-
national level). In more recent times, as individual members
may be remotely located,Web-based telemedicine platforms have
been increasingly utilized. This format is typically not “real-time,”
but rather a “store-and-forward” arrangement whereby clinicians
are able to upload case summaries to seek specific management
advice or opinions.
A number of countries, including Belarus, Belgium, France,
Mexico, Portugal, and the UK have implemented national
level TB consilia (11, 12). These were compared in a recent
review (11). Notably, a number of countries were using email-
based discussion, which has privacy and legal implications,
particularly where identifiable data or clinical images are used
(13). Alternately, other countries utilized a regular (monthly)
meeting, with attendance either in person or remotely. However,
this may not be ideal in terms of timely advice for patient care.
The European Respiratory Society (ERS)/WHO electronic
consilium (14) was a supranational, free-to-access, bilingual,
Web-based consilium service. Between 2013 and 2018, this
system managed more than 400 TB cases from a number of
different continents (10). Following the success of the ERS/WHO
consilium, a newly promoted initiative: the Global TB Network,
was launched in 2018, incorporating a Global TB consilium (15).
An additional feature of this network is the provision of support
for the management of latent TB infection, an area for which
there is increasing focus.
In many medium and high TB incidence settings, TB consilia
have acted as an approval or consensus decision system for
accessing new drugs or regimens for MDR TB, specifically
relating to the use of the new TB drugs: bedaquiline and
delamanid (11, 16, 17). Initially, from 2013, where access to
these drugs was only via compassionate access or pilot programs,
this facilitated a “gatekeeper” function with restricted use for
specific indications only. However, with the recent update to
WHO treatment guidelines for MDR TB (5), bedaquiline is
now recommended upfront for all patients with MDR TB,
and hence should no longer require approval for procurement
and administration unless supplies are limited and therefore
prioritized. In some countries, Delamanid remains on special
access mechanisms, such as compassionate use basis and
hence consilia remain the main way of approval for accessing
the drug.
Finally, consilium can serve an educational role: for clinicians
to review how previous similar cases have beenmanaged, and also
to have direct access to seek guidance from experienced advisors
and mentors. Submitted cases may be rare, unusual or the first
experience with a particular regimen or combination of drugs
(18), in which case sharing of experience can be beneficial.
Case Study: Telemedicine to Support
MDR-TB Care in Papua New Guinea
Papua New Guinea (PNG) is classified as a high burden country
for MDR-TB, TB and TB/HIV by the WHO. It has the highest
estimated TB incidence rate in the Western Pacific region at
432 per 100,000 people (1). An unprecedented outbreak of
MDR-TB has been reported on Daru Island in the Western
Province of PNG (19). This led to the establishment of the
emergency response task force for MDR-TB in 2014, led by
the National Department of Health in PNG with support from
the Australian Government, across three identified “hotspot”
provinces, including Daru,Western Province. The programmatic
interventions during the response in Daru 2014-17 and clinical
care model have been described elsewhere (20, 21).
The Burnet Institute, based in Australia, has been the technical
assistance partner in the multi-stakeholder response in Western
Province through the RID-TB project (Reducing the Impact
of Drug-resistant TB in Western Province) since August 2014.
The RID-TB project supports the provincial TB program in
program design and evaluation, implementation, clinical care,
capacity building and training, health systems strengthening and
operational research. The RID-TB project staff include long term
advisors (remote/visiting) and field-based TB specialists. Clinical
care is provided by medical officers and health workers at Daru
General Hospital. A clinical expert group (CEG) (or consilium)
was formed to support MDR-TB care and provide advice,
primarily on patients to whom the standardized care pathway
did not apply e.g., pediatric cases, extra-pulmonary TB, TB-
HIV, extensively drug-resistant TB (XDR-TB) and management
of adverse effects or complex cases. In particular, there was a
need to provide clinical consensus decision for patients initiated
on newer TB drugs—bedaquiline and delamanid—which were
initially obtained via compassionate access, and for which there
was limited in-country experience.
Because of the remote location, the CEG initially
communicated de-identified case discussions on email and
a file server for records. After assessment of various options,
the project implemented a telemedicine platform in April 2016:
Collegium Telemedicus (22). The choice of platform was based
on the considerations of data security and accountability, cost,
bandwidth requirements, ease of use, and the capacity for two-
way discussions between clinicians and the CEG. The platform
allows users to submit case summaries, and also to attach
relevant results, to assist in interpretation e.g., X ray images or
electrocardiogram (ECG) records. Our CEG is comprised of a
group of technical experts with a broad range of international
experience, who are also familiar with the Daru context. Because
of time limitations and varying availability, the group has a
monthly roster, to ensure that there is always a timely response,
although areas of expertise can be drawn on for specific cases.
The objectives of the consilium/CEG: are to provide clinical
support in complex case management, with the additional
functions of capacity building, quality assurance, and the
formation of collaborations between physicians from different
locations (e.g., Daru General Hospital, Port Moresby General
Hospital and the National TB Program).
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TABLE 1 | Benefits and challenges of the telemedicine platform.
Domain Benefits Challenges
Clinical support in complex case
management
• Expert input within 24–48 h
• Continuity of care with one record of all discussions
• Consensus expert opinion for challenging cases
• Multi-disciplinary expert advice including infectious diseases,
pediatrics, radiology, and other specialists
• Continuity of clinical advice from experts who know and have
worked in the program
• Consensus opinion for treatment initiation with new drugs,
bedaquiline, delamanid, initially under compassionate access
• Internet access variable requiring considerable time at
field level to load cases and responses
• Variability in initiation of referrals depending on
preference of clinical staff in the field
• Difficult to link patient notes from patients with more
than one treatment episode
Capacity building • Inclusion of recent evidence and guidelines within responses
• Previous cases available for learning by new staff
• Two-way process with discussions of cases
• Training for new staff on use of protocols in difficult cases
• High turnover of staff in the field limiting longer term
capacity building
Quality assurance of clinical practice • Potential for audits of quality of care and expert advice
• Support of roll out of active drug safety monitoring
• Audits not linked in with national quality
assurance systems
Formation of collaborations between
physicians from different locations
• Strengthened links between Daru team and technical
assistance partner
• System currently only used in one site within PNG
From April 2016 to February 2019, 237 cases were discussed
using the platform. This encompassed diagnostic (presumptive)
and treatment cases. More recently, support to the scale up of
preventative therapy for latent TB infection has been included.
Across this time period, there have been 44 different “user”
accounts (either with the capacity to make referrals, or view
only for educational purposes), and a current pool of five
technical experts providing technical support and advice across
a range of areas. The median response time from referral for
cases was relatively prompt at 17.6 h, facilitating timely decision
making. The median number of messages exchanged for each
case was 10, reflecting the amount of user engagement and
discussions occurring.
The program has seen a high turnover of field-based staff,
due to the remote and challenging context. As a result, there
can be some variation in practices with different clinicians and
one key benefit of Collegium Telemedicus that we have noted is
for continuity of patient care. With patients often encountering
several different clinicians across their “journey,” this allows
transparency in the rationale for previous decision making. As
a learning tool, the consilium has also served as a useful resource
to explore how similar patients may have been approached in the
past e.g., MDR-TB infections in pregnancy.
The telemedicine service facilitated the uptake of innovations
where technical support was required. The programmatic use
of the TB drug Bedaquiline was scaled up in PNG in 2016,
procured by the National TB Program, and supported by the
global donation program (21). In this context, the consilium
proved useful in supporting local clinical decision making in the
scale up of this drug where there was little previous in-country
experience and a limitation on its supply. There were 75 cases in
which the use of Bedaquiline was discussed or mentioned, with a
high frequency of discussions occurring in the initial period (26
cases in the first 12 months), which has appeared to decrease as
clinicians gained familiarity with use of the drug (15 cases in the
last 12 months).
A number of progress/feedback reports were completed by
program participants. Of the five reports that were completed
across 2016–2018, all respondents felt that the responses they
received on Collegium Telemedicus were timely and well-
adapted to the local environment. However, in response to
whether there would be a benefit to the eventual outcome for
the patient, two participants responded “yes,” two responded
“perhaps” and one responded “no”. Three of the five respondents
felt that there was educational benefit in the process.
Although there were a number of concurrent interventions
across this time period, we believe that this service has
contributed, in part, to the very good outcomes now seen for
MDR-TB patients in Daru (20, 21). Treatment success rates for
the 2015 MDR TB enrolment cohort were 81%, with only 4% of
patients being lost to follow up and 4% failing treatment (20).
An analysis of the perceived benefits and challenges of the
telemedicine platform according to the defined objectives, is
provided in Table 1. There have been a number of challenges
throughout the implementation process including high field-
staff turnover and variable engagement depending on staff
preferences. Internet access and connectivity has been a limiting
issue at times, despite the low bandwidth requirements. While
expansion to telemedicine services that incorporate real-time
video linkages is an appealing option, it is currently still not
possible for many rural sites in PNG.
CONCLUSION
Implementation of the WHO End TB strategy will require
ongoing innovation and the introduction of new treatments
and care models for MDR-TB. The WHO guidelines will have
a number of significant and ongoing updates as new evidence
is generated, in particular for MDR-TB treatment. These will
require technical assistance in resource-limited settings, where
training and capacity gaps may exist.
The RID-TB technical assistance project in Daru, a remote
and resource limited setting in PNG, implemented a telemedicine
platform to optimize MDR-TB patient care. The telemedicine
platform supported high quality clinical care and fostered
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collaboration between clinicians and technical experts in a shared
learning environment. In particular, it bridged the knowledge-
delivery gap in supporting the scale-up of innovations such as
implementation of bedaquiline for MDR-TB and management of
complex cases.
Telemedicine is a key intervention to optimize patient
care and build local capacity and clinical collaborations in
the management of MDR-TB in low resourced settings,
particularly in the landscape of new and emerging evidence
and evolving standards of care in MDR-TB anticipated in the
coming decade.
DATA AVAILABILITY
The datasets for this manuscript are not publicly available.
Requests to access the datasets should be directed to
khai.huang@burnet.edu.au.
AUTHOR CONTRIBUTIONS
GH, GP, RW, PdC, and SM: concept. GH and RW: acquisition of
data. GH, GP, DO’B, PdC, RW, and SM: drafting of manuscript.
GH, GP, MT, SH, PU, DO’B, PdC, SG, RW, and SM: critical
review and final approval of manuscript.
FUNDING
The Reducing the Impact of Drug-resistant TB (RID-TB) project
was supported by the Australian Government and implemented
by the Burnet Institute. The Stronger Systems for Drug-resistant
Tuberculosis and Malaria research grant was supported by the
Australian Government and implemented by the Menzies School
of Health Research and the Burnet Institute. The views expressed
in this publication are the author’s alone and are not necessarily
the views of the Australian Government.
REFERENCES
1. World Health Organization. Global Tuberculosis Report 2018. Licence: CC
BY-NC-SA 3.0 IGO (2018). Available online at: https://www.who.int/tb/
publications/global_report/en/ (accessed March 14, 2019).
2. World Health Organization (2015). The END TB Strategy. Available online at:
https://www.who.int/tb/strategy/End_TB_Strategy.pdf (accessed March 14,
2019).
3. Review on Antimicrobial Resistance. Tackling Drug-Resistant Infections
Globally: Final Report and Recommendations. (2016). Available online
at: https://amr-review.org/sites/default/files/160525_Final%20paper_with
%20cover.pdf (accessed March 14, 2019)
4. Francis JR, Manchikanti P, Blyth CC, Denholm J, Lowbridge C, Coulter C,
et al. Multidrug-resistant tuberculosis in Australia, 1998–2012. Int J Tuberc
Lung Dis. (2018) 22:294–9. doi: 10.5588/ijtld.17.0412
5. World Health Organization. Treatment Guidelines for Multidrug- and
Rifampicin-Resistant Tuberculosis. (2018). Accessible online at: https://www.
who.int/tb/publications/2018/WHO.2018.MDR-TB.Rx.Guidelines.prefinal.
text.pdf?ua=1 (accessed March 14, 2019).
6. Farmer PE. Chronic infectious disease and the future of health care delivery.
N Engl Journal of Med. (2013) 369:2424–36. doi: 10.1056/NEJMsa1310472
7. ReidMJ, Arinaminpathy N, BloomA, Bloom BR, Boehme C, Chaisson R, et al.
Building a tuberculosis-free world: the lancet commission on tuberculosis.
Lancet. (2019) 393:1331–84. doi: 10.1016/S0140-6736(19)30024-8
8. Wootton R, Bonnardot L. Telemedicine in low-resource settings. Front Public
Health. (2015). 3:3. doi: 10.3389/fpubh.2015.00003
9. World Health Organization. Digital Health for the END TB Strategy: an
Agenda for Action. (2015). Available online at: https://www.who.int/tb/areas-
of-work/digital-health/Digital_health_EndTBstrategy.pdf?ua=1 (accessed
March 22, 2019).
10. Tiberi S, Pontali E, Tadolini M, D’Ambrosio L, Migliori GB. Challenging
MDR-TB clinical problems–The case for a new Global TB Consilium
supporting the compassionate use of new anti-TB drugs. Int J Tuberc Lung
Dis. (2019) 80:S68–72. doi: 10.1016/j.ijid.2019.01.040
11. D’ambrosio L, Bothamley G, Luna JC, Duarte R, Guglielmetti L, Torrico
MM. et al. Team approach to manage difficult-to-treat TB cases:
experiences in Europe and beyond. Pulmonology. (2018) 24:132–41.
doi: 10.1016/j.rppnen.2017.10.005
12. Jordan TS, Cullen D, Davies PD. A centralised electronic Multidrug-Resistant
Tuberculosis Advisory Service: the first 2 years. Int J Tuberc Lung Dis. (2012)
16:950–4. doi: 10.5588/ijtld.11.0411
13. Mahar PD, Foley PA, Sheed-Finck A, Baker CS. Legal considerations of
consent and privacy in the context of clinical photography in Australian
medical practice.Med J Aust. (2013) 198:48–9. doi: 10.5694/mja12.11086
14. Blasi F, Dara M, Van Der Werf MJ, Migliori GB. Supporting TB clinicians
managing difficult cases: the ERS/WHO Consilium. Eur Respir J. (2013)
41:491–4. doi: 10.1183/09031936.00196712
15. Silva DR, Rendon A, Alffenaar JW, Chakaya JM, Sotgiu G, Esposito
S, et al. Global TB Network: working together to eliminate
tuberculosis. Jornal Brasileiro de Pneumologia. (2018) 44:347–9.
doi: 10.1590/S1806-37562018000000279
16. Hafkin J, Hittel N, Martin A, Gupta R. Early outcomes in MDR-TB and XDR-
TB patients treated with delamanid under compassionate use. Eur Respir J.
(2017) 50:1700311. doi: 10.1183/13993003.00311-2017
17. Hafkin J, Hittel N, Martin A, Gupta R. Compassionate use of
delamanid in combination with bedaquiline for the treatment of
multidrug-resistant tuberculosis. Eur Respir J. (2019) 53:1801154.
doi: 10.1183/13993003.01154-2018
18. Tadolini M, Lingtsang RD, Tiberi S, Enwerem M, D’Ambrosio L, Sadutshang
TD, et al. First case of extensively drug-resistant tuberculosis treated
with both delamanid and bedaquiline. Eur Respir J. (2016) 48:935–8.
doi: 10.1183/13993003.00637-2016
19. Kase P, Dakulala P, Bieb S. Outbreak of multidrug-resistant tuberculosis
on Daru Island: an update. Lancet Respir Med. (2016). 4:e80.
doi: 10.1016/S2213-2600(16)30094-7
20. Morris L, Hiasihri S, Chan G, Honjepari A, Tugo A, Taune M, et al.
The emergency response to multidrug-resistant tuberculosis in daru,
western province, papua new Guinea, 2014-2017. Public Health Action.
(in Press).
21. Taune T, Ustero P, Hiasihri S, Huang K, Aia P, Morris L, et al. Successful
implementation of bedaquiline for multidrug-resistant tuberculosis in Daru,
a remote setting in Papua New Guinea. Public Health Action. (in Press).
22. Wootton R, Wu WI, Bonnardot L. Nucleating the development
of telemedicine to support healthcare workers in resource-limited
settings: a new approach. J Telemed Telecare. (2013) 19:411–7.
doi: 10.1177/1357633X13506511
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2019 Huang, Pawape, Taune, Hiasihri, Ustero, O’Brien, du Cros,
Graham, Wootton and Majumdar. This is an open-access article distributed
under the terms of the Creative Commons Attribution License (CC BY). The use,
distribution or reproduction in other forums is permitted, provided the original
author(s) and the copyright owner(s) are credited and that the original publication
in this journal is cited, in accordance with accepted academic practice. No use,
distribution or reproduction is permitted which does not comply with these terms.
Frontiers in Public Health | www.frontiersin.org 5 August 2019 | Volume 7 | Article 222
